Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Sergio Vaño-Galván and John McCoy.
Sergio Vaño-Galván
Connection Strength
1.702
John McCoy
  1. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. Front Med (Lausanne). 2021; 8:668698.
    View in: PubMed
    Score: 0.239
  2. Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. Med Hypotheses. 2021 01; 146:110439.
    View in: PubMed
    Score: 0.229
  3. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):e243-e246.
    View in: PubMed
    Score: 0.229
  4. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e15-e17.
    View in: PubMed
    Score: 0.227
  5. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul; 19(7):1542-1543.
    View in: PubMed
    Score: 0.222
  6. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020 11; 81(7):771-776.
    View in: PubMed
    Score: 0.221
  7. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021 Feb 22; 13(2):e13492.
    View in: PubMed
    Score: 0.058
  8. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2021 Jan; 35(1):e13-e15.
    View in: PubMed
    Score: 0.057
  9. Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020 12; 83(6):e453-e454.
    View in: PubMed
    Score: 0.056
  10. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug; 83(2):680-682.
    View in: PubMed
    Score: 0.055
  11. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul; 19(7):1545-1547.
    View in: PubMed
    Score: 0.055
  12. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul; 33(4):e13365.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.